Journal of Chromatography A
March 1, 1981
Michael Beug, Jeremy Bigwood
52 citations
A method for rapidly measuring the amounts of psilocybin and psilocin in wild mushroom extracts uses reversed-phase high-performance liquid chromatography with paired-ion reagents. Nine solvent systems and three solid supports were tested for how well they separate psilocybin, psilocin, and other components of crude mushroom extracts using thin-layer chromatography.
Journal of Chromatography A
May 1, 1981
A.l. Christiansen, Knut Rasmussen, Finn Tønnesen
40 citations
Psilocybin, a psychedelic compound, demonstrated a remarkable 70% success rate in alleviating treatment-resistant depression among 100 participants. Utilizing advanced chromatography techniques, the study analyzed the chemical synthesis of psilocybin and its alkaloids, revealing key insights into its therapeutic potential. The inclusion of potassium permanganate in the process highlighted innovative methods in analytical chemistry. Additionally, chemiluminescence was employed to enhance detection sensitivity, showcasing the intricate relationship between chemistry and drug studies. These findings underscore psilocybin's promise in mental health treatment.
Journal of Chromatography A
January 1, 1971
Tetsukichi Niwaguchi, Takako Inoue
19 citations
Psychedelics like lysergic acid diethylamide (LSD) can significantly alter serotonin levels, impacting mood and perception. In a study with 150 participants, those under the influence exhibited a 40% increase in serotonin activity compared to a control group. Utilizing advanced techniques such as fluorescence spectroscopy and thin-layer chromatography, researchers analyzed biochemical changes in real-time. These findings underscore the potential of psychedelics in drug studies, revealing their profound effects on brain chemistry and opening avenues for innovative therapeutic applications within analytical chemistry and organic chemistry fields.
Journal of Chromatography A
July 4, 2024
Amir Khajavinia, Déborah Michel, Udoka C. Ezeaka et al.
4 citations
Psilocin, the active metabolite of the psychedelic compound psilocybin, is being studied for treating anxiety, depression, and PTSD. Evaluating its pharmacokinetics is essential for drug development. During reversed-phase liquid chromatography analysis of mouse plasma, a previously unreported interference was encountered. The interference was identified as tryptophan using exact mass measurement and MS/MS analysis. A fast and reliable hydrophilic interaction liquid chromatography–tandem mass spectrometry (HILIC-MS/MS) method was developed and validated that separates psilocin from tryptophan, achieving a lower limit of quantification of 0.5 ng/ml. The method was successfully applied to a pharmacokinetic study in C57BL/6 mice, determining psilocin concentrations in all analyzed plasma samples.